Age-Related Macular Degeneration Market Report 2026

Age-Related Macular Degeneration Market Overview

• Age-Related Macular Degeneration market size has reached to $10.67 billion in 2025 • Expected to grow to $15.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: The Surging Prevalence Of Age-Related Macular Degeneration Sparks Growth In The AMD Market • Market Trend: Advancements in AMD Therapy: The Role of Fab and MAR Systems • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Age-Related Macular Degeneration Market?

Age-related macular degeneration (AMD) refers to a progressive eye condition in which the macula, which is located at the center of the retina, deteriorates over time in individuals with AMD, leading to a decline in central vision. It is due to aging. The therapy options for age-related macular degeneration include regular eye exams, lifestyle changes, and particular nutritional supplements. The main types of age-related macular degeneration are wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD). Wet age-related macular degeneration refers to a progressive eye disease in which abnormal blood vessels start growing beneath the macula, which is the central part of the retina responsible for sharp, central vision. It uses various drugs such as eylea, lucentis, vastin, and others. It is applied intravenously and intravitreally, and are distributed through hospital pharmacies, specialty pharmacies, and online pharmacies.

What Is The Age-Related Macular Degeneration Market Growth Forecast?

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $15.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to development of next-generation anti-vegf drugs, growing investment in ophthalmology research, expansion of specialty pharmacies and online pharmacy channels, increasing use of combination therapies, rising adoption of personalized treatment approaches. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of nutritional supplements and low vision aids, growth in photodynamic and laser therapy procedures, expansion of intravitreal and intravenous administration routes, increasing awareness and regular eye screening programs.

Global Age-Related Macular Degeneration Market Segmentation

1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD) 2) By Drug: Eylea, Lucentis, Avastin, Other Drugs 3) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy Subsegments: 1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery 2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy

What Is The Driver Of The Age-Related Macular Degeneration Market?

Rising age-related macular degeneration (AMD) prevalence is expected to propel the growth of the age-related macular degeneration (AMD) market going forward. Age-related macular degeneration (AMD) is a progressive eye condition affecting the macula, a small part of the retina responsible for central vision. Age-related macular degeneration (AMD) treatments support patients suffering from retinal disorders by minimizing the severity of the disease condition. For instance, in February 2023, according to the reports shared by Optimaxa, a UK-based laser eye treatment specialist, age-related macular degeneration (AMD) affected 196 million individuals globally and is expected to reach 288 million in 2040, accounting for 8.7 percent of the world's population. Therefore, rising age-related macular degeneration (AMD) prevalence is driving the age-related macular degeneration industry.

Key Players In The Global Age-Related Macular Degeneration Market

Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

Global Age-Related Macular Degeneration Market Trends and Insights

Major companies in the age-related macular degeneration (AMD) market are advancing innovative technologies, such as recombinant antigen-binding fragments. Recombinant antigen-binding fragments (Fab) are engineered proteins derived from antibodies that specifically bind to target antigens, commonly utilized in therapeutic applications to inhibit disease-related pathways. For instance, in December 2023, Enzene Biosciences, an India-based biotechnology company, launched ranibizumab, a recombinant monoclonal antibody fragment (Fab) specifically engineered to inhibit vascular endothelial growth factor (VEGF), a key protein involved in the development of abnormal blood vessels in conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). By obstructing VEGF, ranibizumab effectively decreases the leakage and proliferation of these blood vessels, which helps preserve vision in patients with these retinal disorders. It is delivered through intravitreal injection and has gained widespread acceptance in clinical practice for its efficacy in treating various retinal diseases. The introduction of ranibizumab has greatly enhanced the treatment landscape for patients grappling with these serious conditions.

What Are Latest Mergers And Acquisitions In The Age-Related Macular Degeneration Market?

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc., for $5.9 billion. Through this acquisition, Astellas Pharma Inc. aims to expand its presence in the ophthalmology market and accelerate the development of novel treatments in the field of ophthalmology. IVERIC Bio Inc. is a US-based biotech corporation that develops age-related macular degeneration drugs and products for treatment.

Regional Outlook

North America was the largest region in the global age-related macular degeneration market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Age-Related Macular Degeneration Market?

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Age-Related Macular Degeneration Market Report 2026?

The age-related macular degeneration market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.